Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
By M. Gerlinger, A. Rowan, S. Horswell, M. Math, J. Larkin, D. Endesfelder, E. Gronroos, Pierre Martinez, N. Matthews, A. Stewart and 21 more. New England Journal of Medicine, 2012
7,381 citations recorded by the source corpus.
Background Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. Methods To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. Results Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. Conclusions Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.)
Subfields: Cancer Research, Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/b97108a8e1dd8cf67ff9f374a8237fabf4c96ad4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- K. Pantel
- R. Weinberg
- C. Alix‐Panabières
- D. Pattabiraman
- Gad Getz
- Arthur W. Lambert
- Charles Swanton
- Nicholas McGranahan
In Physiology
- Antonija Krešo
- K. Polyak
- A. Marusyk
- C. López‐Otín
- O. Farokhzad
- N. Bertrand
- William C. Hahn
- R. Weinberg
In Pulmonary and Respiratory Medicine
- Hugo J. W. L. Aerts
- William Pao
- Chintan Parmar
- Philippe Lambin
- Gregory Riely
- P. Jänne
- Vincent A. Miller
- John Quackenbush
Citations in the corpus
- Liquid biopsy: current technology and clinical applications (2022, background): “Single tumor-biopsy samples can lead to an underestimation of the tumor genomic landscape given intratumor heterogeneity [51].”
- Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach (2014, background): “It is known that multiple subclonal populations coexist within tumours, reflecting extensive intratumoral ‘somatic evolution’ 15,16 .”
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma (2015, background): “Given that LC was confirmed at the autopsy of BMBC2, our results indicated that the CSF Genev Amino acid BM (1) BM (2) BM (3) Liver (1) Liver (2) Liver (3) Liver (4) Liver (5) Liver (6) Gastric CSF ctDNA Plasma ctDNA TBX3 K137fs TP53 P177fs MAP2K4 E372X NCOR1 R507X ASXL2 A1269I FLT3 T820S MET N1081H”
- Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “Even if one metastatic lesion can be biopsied, substantial genetic heterogeneity of metastatic lesions located at different sites in the same patient has been demonstrated (111).”
- Intratumor heterogeneity: evolution through space and time. (2012, background): “In the case of renal cancer, such trunk events would be represented by VHL or PBRM1 somatic mutations (14).”
- Cancer epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance (2014, background): “This would be a factor in countering the strictly hierarchical theory for existence of CSCs as a stable population, with unrestricted tumor initiating potential that always give rise to progeny cells lacking or reduced for the tumor-initiating property (Greaves and Maley, 2012; Gupta et al., 2011).”